Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2026 06:15 ET | Source: F. Hoffmann-La Roche Ltd

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMDPositive recommendation is based on data from the LADDER, Archway and...
July 23, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and...
July 23, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens

Konzernverkäufe stiegen in den ersten sechs Monaten um +6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -2% und auf USD-Basis2 +8%) aufgrund hoher Nachfrage nach innovativen Medikamenten und...
July 15, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy

Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus1 If approved,...
July 14, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis

The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response.Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form...
July 09, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche receives CE Mark for blood test to identify tuberculosis infection

The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets.Performed on Roche’s industry-leading...
July 07, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC

Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa BrainshuttleTM AD study and design of Phase III PrevenTRON study in...
July 02, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in...
June 30, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double...
June 29, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of...